ライブラリ登録: Guest
Begell Digital Portal Begellデジタルライブラリー 電子書籍 ジャーナル 参考文献と会報 リサーチ集
Critical Reviews™ in Oncogenesis
SJR: 0.631 SNIP: 0.503 CiteScore™: 2

ISSN 印刷: 0893-9675
ISSN オンライン: 2162-6448

Critical Reviews™ in Oncogenesis

DOI: 10.1615/CritRevOncog.v17.i1.60
pages 69-95

Targeting PI3 Kinase/AKT/mTOR Signaling in Cancer

Karen Sheppard
Division of Cancer Research, Peter MacCallum Cancer Centre , Department of Biochemistry and Molecular Biology
Kathryn M Kinross
Division of Cancer Research, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
Benjamin Solomon
Division of Cancer Research, Division of Cancer Medicine, and Sir Peter MacCallum Department of Oncology, and the Monash University, Clayton, Australia
Richard B. Pearson
Division of Cancer Research, Department of Biochemistry and Molecular Biology, Sir Peter MacCallum Department of Oncology, and the Department of Biochemistry and Molecular Biology, Monash University, Clayton, Australia
Wayne A. Phillips
Division of Cancer Research, Division of Cancer Surgery, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; Sir Peter MacCallum Department of Oncology, and the Department of Surgery (SVH), University of Melbourne, Parkville, Australia

要約

The phosphatidylinositol 3 kinase (PI3K) pathway is one of the major pathways modulating cell growth, proliferation, metabolism, survival, and angiogenesis. Hyperactivation of this pathway is one of the most frequent occurrences in human cancer and is thus an obvious target for treatment of this disease. Currently there are 26 novel compounds targeting the PI3K pathway being assessed in more than 150 cancer-related clinical trials. Although this pathway is involved in many vital biologic functions, data emanating from these clinical trials indicate that these drugs are well tolerated. This review outlines the interaction of the PI3K pathway with other signaling cascades, highlights mechanisms involved in hyperactivation, discusses current therapeutics in cancer-related clinical trials that target this pathway, and, based on preclinical data, discusses possible leads on patient selection and combinational therapy, including targeting multiple components of the associated signaling network.


Articles with similar content:

Epidermal Growth Factor Receptor Tyrosine Kinase: A Potential Target in Treatment of Non-Small-Cell Lung Carcinoma
Journal of Environmental Pathology, Toxicology and Oncology, Vol.36, 2017, issue 2
Niranjali Devaraj, Venugopal Vinod Prabhu
The Tumor Microenvironment: A Target for Combination therapy of Breast Cancer
Critical Reviews™ in Oncogenesis, Vol.18, 2013, issue 1 - 2
Ralph A. Reisfeld
Natural Products as Inhibitors of Epidermal Growth Factor Receptor
Forum on Immunopathological Diseases and Therapeutics, Vol.2, 2011, issue 4
Thomas Efferth
Regulating RNA Binding Motif 5 Gene Expression− A Novel Therapeutic Target for Lung Cancer
Journal of Environmental Pathology, Toxicology and Oncology, Vol.36, 2017, issue 2
Niranjali Devaraj, Venugopal Vinod Prabhu
Diverse Signaling Pathways and Current Status of Molecular Targeted Treatments for Hepatocellular Carcinoma
Critical Reviews™ in Eukaryotic Gene Expression, Vol.27, 2017, issue 4
Ali Sharif, Wafa Majeed, Bushra Akhtar, Muhammad Furqan Akhtar, Faqir Muhammad